KNB Kanabo Group Plc

TIDMKNB

RNS Number : 9997U

Kanabo Group PLC

31 March 2023

31 March 2023

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

Directorate Change

Kanabo Group plc (LSE: KNB), a leading patient-focused healthtech ecosystem and provider of personalised medicinal treatments, announces that Dan Poulter has stepped down as Non-Executive Director ("NED") to focus on existing commitments outside of the business.

Kanabo is at very advanced stages of appointing a new UK-based NED to join the Board of Directors, and a further announcement about this will be made imminently.

David Tsur, Chairman of Kanabo, commented:

"I would like to thank Dan for his contribution to the Company. He has been a pleasure to work with and we wish him every success in the future."

Enquiries:

 
Kanabo Group plc                                        via Vigo Consulting 
 Avihu Tamir, Chief Executive Officer                   +44 (0)20 7390 0230 
 Assaf Vardimon, Chief Financial Officer 
Peterhouse Capital Ltd (Financial Adviser 
 and Broker) 
 Eran Zucker/ Lucy Williams / Charles Goodfellow        +44 (0)20 7469 0930 
Vigo Consulting (Financial Public Relations/Investor 
 Relations) 
 Jeremy Garcia / Fiona Hetherington / Verity 
 Snow                                                        +44 (0)20 7390 
 kanabo@vigoconsulting.com                                             0230 
 

About Kanabo Group Plc

Founded in 2017, Kanabo Group Plc (LSE:KNB) is a patient-first HealthTech ecosystem, focused on delivering high quality and innovative medical treatments, via its leading-edge technology platform and disruptive product offering.

The Company is a world leader in the research, development and commercialization of regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

Patient care is delivered via the company's NHS-approved online telehealth platform offering video consultations, online prescriptions and access to primary care services. In January 2023, the Company successfully combined its technological and product expertise to launch the Beta phase of its medical cannabis business, initially for chronic pain management, under the new Treat-It brand.

Kanabo Group is committed to evolving more accessible healthcare experiences for every patient.

Visit www.kanabogroup.com for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFLFVVVIILVIV

(END) Dow Jones Newswires

March 31, 2023 09:40 ET (13:40 GMT)

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Kanabo (LSE:KNB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024